I don't think it is a coincidence that news about this failed study was released post-ASCO. Who wants to discuss failure in front of 100,000 clinicians, cancer docs and researchers! Expect more announcements like this in the weeks and months to come:The Associated Press June 9, 2010Human Genome Sciences says cancer drug fails studyROCKVILLE, Md.
Is Onyx Pharmaceuticals' new, next generation proteasome inhibitor a new miracle drug—or just another “bit player” on the multiple myeloma scene? It depends who you ask.The company is pushing comparisons with the only currently available FDA proteasome inhibitor, Velcade. Company officials point to ongoing research study results which show less risk of developing peripheral neuropathy
I am blogging live from the east wing of McCormick Place here on Chicago's lakefront. The room is large--I estimate there are about 1400 myeloma docs, researchers and clinicians here. Dr. Vij is speaking about the new 004 carfilzomib study. This particular event is chaired by Dr. Chanan-Khan, representing Roswell Park Cancer Institute, and Dr.
Follow-Up Analysis Of Onyx Pharmaceuticals’ Carfilzomib 004 Study Against Refractory Multiple Myeloma
Onyx Pharmaceuticals' Carfilzomib Highlights First Day Of ASCO Meetings In ChicagoFlaunting an impressive 55% success rate in previously treated multiple myeloma patients, Onyx Pharmaceuticals revealed the results of their ongoing Phase 2 clinical carfilzomib study, 004 at the American Society of Clinical Oncology (ASCO) meetings here in Chicago.Carfilzomib is a selective, next-generation proteasome inhibitor, similar
Here is the first of two major announcements by Onyx Pharmaceuticals concerning their new multiple myeloma drug carfilzomib:Onyx Pharmaceuticals’ Carfilzomib Continues to Demonstrate Encouraging Results in Ongoing Phase 2 Multiple Myeloma StudyFifty-five Percent Single-Agent Response Rate in Relapsed/Refractory SettingEmeryville, CA – June 5, 2010 – Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced interim results from
Well, I’ve begun to learn my way around McCormick place. There is a large, central building (East Hall) which houses registration and a number of presentation rooms. Crossing over by sky-walk heading west, you enter a huge, glass covered atrium and exhibit hall. This is where all of the drug and medical equipment companies have
Oh my God! I I don't know how I ever would have managed driving into the city and finding the press room here at McCormick Place if I hadn't grown up in the Chicago area... Traffic is crazy, parking unclear and the facility is massive! I'm hiding here in the press room and preparing for
More pre-ASCO news:Multiple Myeloma Research Consortium (MMRC) Announces Data Presentations at 46th Annual American Society of Clinical Oncology (ASCO) Annual MeetingThe Multiple Myeloma Research Consortium (MMRC) today announced the presentation of studies conducted through its clinical sites in collaboration with industry partners, Onyx Pharmaceuticals and Bristol-Myers Squibb, in evaluating promising new therapeutic agents for multiple
What causes multiple myeloma? I just posted a link to a story about Agent Orange causing blood cancers on http://www.helpwithcancer.org/. Multiple myeloma is on that list. However, except for extreme cases, it is tough to prove a cause and effect relationship between the enviornment and the development of multiple myeloma in specific patients.In a recent